Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

The Supreme Court will hear oral arguments Monday in a case that could affect what kind of preventive care is covered at no ...

A new AAA Foundation for Traffic Safety (FTS) report researches and provides suggestions for how tow trucks and other ...

In a statement today, GlaxoSmithKline Malaysia (GSK) highlighted that RSV is a common and highly contagious virus that can lead to serious health complications, including lower respiratory tract ...

A federal panel of medical experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. The 15-member ...

This month: shorter recovery after TAVI, Down syndrome CV insights, the benefits of brisker walking, and more.

A HORRIFIED dad has spoken of how he has watched not one daughter, but both fight for their lives in hospital. “It turns out ...

China is not as big a player in the manufacturing of key ingredients used to make brand and generic medicines as previously ...

Canada is just emerging from another winter wave of multiple infectious diseases only for the population to be confronted ...